Evidence map›Paper›PMID 30011200›Full record

ArticleJournal of the American Chemical Society2018

No Structure-Switching Required: A Generalizable Exonuclease-Mediated Aptamer-Based Assay for Small-Molecule Detection.

Juan Canoura, Zongwen Wang, Haixiang Yu, Obtin Alkhamis, Fengfu Fu, Yi Xiao

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Dissociation Constant (KSmall methods · 2025
    Review
  6. Review
  7. High-Affinity Aptamers forJournal of the American Chemical Society · 2024
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Accelerating Post-SELEX Aptamer Engineering Using Exonuclease Digestion.Journal of the American Chemical Society · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Juan CanouraDepartment of Chemistry and Biochemistry , Florida International University , 11200 Southwest Eighth Street , Miami , Florida 33199 , United States.
Zongwen WangDepartment of Chemistry and Biochemistry , Florida International University , 11200 Southwest Eighth Street , Miami , Florida 33199 , United States.
Haixiang YuDepartment of Chemistry and Biochemistry , Florida International University , 11200 Southwest Eighth Street , Miami , Florida 33199 , United States.
Obtin AlkhamisDepartment of Chemistry and Biochemistry , Florida International University , 11200 Southwest Eighth Street , Miami , Florida 33199 , United States.
Fengfu FuKey Laboratory for Analytical Science of Food Safety and Biology of MOE, Fujian Provincial Key Lab of Analysis and Detection for Food Safety, College of Chemistry , Fuzhou University , Fuzhou , Fujian 350116 , China.ORCID 0000-0002-8823-7672
Yi XiaoDepartment of Chemistry and Biochemistry , Florida International University , 11200 Southwest Eighth Street , Miami , Florida 33199 , United States.ORCID 0000-0001-7278-9811
Florida International University · USFuzhou University · CN

Funding

Aptamer-Based, Exonuclease-Amplified, Colorimetric, Onsite Screening of Methylenedioxypyrovalerone (MDPV) and Mephedrone in Oral FluidR15DA036821 · NIDA · FLORIDA INTERNATIONAL UNIVERSITY · PI XIAO, YI · 2015 to 2015
$337k
NIDA NIH HHS R15 DA036821
6 · The paper itself

Abstract

The binding of small molecules to double-stranded DNA can modulate its susceptibility to digestion by exonucleases. Here, we show that the digestion of aptamers by exonuclease III can likewise be inhibited upon binding of small-molecule targets and exploit this finding for the first time to achieve sensitive, label-free small-molecule detection. This approach does not require any sequence engineering and employs prefolded aptamers which have higher target-binding affinities than structure-switching aptamers widely used in current small-molecule detecting assays. We first use a dehydroisoandrosterone-3-sulfate-binding aptamer to show that target binding halts exonuclease III digestion four bases prior to the binding site. This leaves behind a double-stranded product that retains strong target affinity, whereas digestion of nontarget-bound aptamer produces a single-stranded product incapable of target binding. Exonuclease I efficiently eliminates these single-stranded products but is unable to digest the target-bound double-stranded product. The remaining products can be fluorescently quantified with SYBR Gold to determine target concentrations. We demonstrate that this dual-exonuclease-mediated approach can be broadly applied to other aptamers with differing secondary structures to achieve sensitive detection of various targets, even in biological matrices. Importantly, each aptamer digestion product has a unique sequence, enabling the creation of multiplex assays, and we successfully demonstrate simultaneous detection of cocaine and ATP in a single microliter volume sample in 25 min via sequence-specific molecular beacons. Due to the generality and simplicity of this assay, we believe that different DNA signal-reporting or amplification strategies can be adopted into our assay for target detection in diverse analytical contexts.

Indexed as

Aptamers, NucleotideCalorimetryCocaineDNAExodeoxyribonucleasesFluorescent DyesAptamers, NucleotideCocaineDNAexodeoxyribonuclease Iexodeoxyribonuclease IIIExodeoxyribonucleasesFluorescent Dyes

Identifiers

PMID30011200
PMCPMC6133295
OpenAlexW2884216928

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.